Publications by authors named "V M Moroz"
Article Synopsis
- GSK3326595 is a selective inhibitor of PRMT5 being tested for treating blood cancers like MDS, CMML, and AML, showing promise in preclinical studies by decreasing cancer cell growth and increasing cell death.
- The study aimed to evaluate the drug's clinical activity, safety, and pharmacokinetics in adults with relapsed myeloid neoplasms, focusing on those who received either 400 or 300 mg daily doses.
- Out of 30 enrolled patients, 17% achieved clinical benefits, primarily those with specific genetic mutations; common side effects included low platelet counts and fatigue, while the drug demonstrated quick absorption characteristics.
Decreased cerebral blood flow (CBF) leads to impaired cerebral hemodynamics, which causes an increased risk of stroke. Revascularization has been shown to improve CBF in patients with moyamoya disease. The study is devoted to the retrospective study of clinical features and cerebral hemodynamic characteristics of 17 patients with moyamoya disease before, during and after surgical treatment using extracranial-intracranial (EC-IC) bypass by STA-MCA type.
View Article and Find Full Text PDFThe design of new effective cancer treatment methods is a promising and important research field in translational medicine. Oncolytic viruses can induce immunogenic cell death by activating the body's immune system to recognize tumor cells. This work presents the results for optimizing the production of recombinant vesicular stomatitis viruses (rVSVs).
View Article and Find Full Text PDFAnti-cancer therapy based on oncolytic viruses (OVs) is a targeted approach that takes advantage of OVs' ability to selectively infect and replicate in tumor cells, activate the host immune response, and destroy malignant cells over healthy ones. Vesicular stomatitis virus (VSV) is known for its wide range of advantages: a lack of pre-existing immunity, a genome that is easily amenable to manipulation, and rapid growth to high titers in a broad range of cell lines, to name a few. VSV-induced tumor immunity can be enhanced by the delivery of immunostimulatory cytokines.
View Article and Find Full Text PDFPurpose: Outcomes for children with relapsed and refractory high-risk neuroblastoma (RR-HRNB) remain dismal. The BEACON Neuroblastoma trial (EudraCT 2012-000072-42) evaluated three backbone chemotherapy regimens and the addition of the antiangiogenic agent bevacizumab (B).
Materials And Methods: Patients age 1-21 years with RR-HRNB with adequate organ function and performance status were randomly assigned in a 3 × 2 factorial design to temozolomide (T), irinotecan-temozolomide (IT), or topotecan-temozolomide (TTo) with or without B.